News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FortuneRock Given Go-Ahead to Begin China Trials of Long-Acting Interferon


8/23/2012 10:07:16 AM

by Richard Daverman, PhD

August 22, 2012 -- FortuneRock of the US has received SFDA approval to begin China clinical trials of its long-acting formulation of Interferon-a2a. Fortune developed the product using its proprietary fusion technology to create a drug that is administered every 14 days. Existing forms of interferon require patients to receive an injection every day or once per week. FortuneRock operates in China through its wholly owned foreign enterprise company, FortuneRock (China) Ltd. More details....


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES